Key Takeaways

  • The FDA decision date for Opus Genetics and Viatris (NASDAQ:VTRS) phentolamine ophthalmic solution is October 17, 2026, according to a PDUFA calendar, so the result is still pending.
  • Roche's Enspryng has an FDA date of October 15, 2026, two days earlier, though the calendar does not list a US ticker for Roche and no tag is used here.
  • The Daiichi Sankyo and Merck ifinatamab deruxtecan BLA was withdrawn, so no FDA decision is anticipated on October 10, a date that appeared on some earlier calendars.
  • Dates come from calendar sites and not from the FDA itself, so Viatris (NASDAQ:VTRS) Market Participants should confirm each date in issuer releases before relying on it.

The Decision Dates

Two FDA dates are close. Enspryng, a Roche medicine, has a decision date of October 15, 2026, and the phentolamine ophthalmic solution being developed by Opus Genetics with Viatris (NASDAQ:VTRS) has a date of October 17. A third item, the Daiichi Sankyo and Merck Biologics license application for ifinatamab deruxtecan, was withdrawn, so no decision is anticipated on October 10. These dates come from review calendars, not from agency statements, and the tickers of the partners were not listed. A PDUFA date is the target by which the FDA aims to act, and the agency can approve, reject or ask for more information, and it sometimes acts early or extends the date.

What Is at Stake

Phentolamine ophthalmic solution is an eye drop under review, and the filing is a collaboration between Opus Genetics and Viatris (NASDAQ:VTRS), which has rights to commercialize it. Viatris is a substantial generic and specialty drug maker, so one eye drop is unlikely to change its financial profile much, while for the smaller partner the decision may be far more material. An approval would let the issuers launch, and a complete response letter would delay launch while they address the FDA's concerns. The Withdrawal of the Daiichi and Merck filing demonstrates that dates on calendars can disappear, which is why a pending date is a possibility, not an actual result, and no result should be assumed.

Principal Risks and Upcoming Developments

The principal risks include a delay, a rejection or conditions on the label, and the result can differ from what a calendar suggests. Investors should monitor for Business releases around October 15 and October 17, 2026, and for an FDA action letter. Broader market conditions also matter: the Nasdaq Composite declined 1.25% during the most recent session and September CPI arrives on October 14, so even good news can be muted. Viatris (NASDAQ:VTRS) has other catalysts, but none are stated here. Readers should treat the calendar dates as unconfirmed, and should not assume that an approval is probable, because the FDA decides on the supporting information in the filing, which is not characterized in the file.

Current Assessment

The FDA is anticipated to act on the Opus Genetics and Viatris eye drop on October 17, 2026, two days after the Enspryng date, but these dates come from calendars and the outcome remains uncertain. The withdrawn Daiichi and Merck filing is a reminder that dates can change. Viatris (NASDAQ:VTRS) should be assessed using the actual FDA action. Investors may wish to await confirmation in business filings and the next trading sessions before drawing conclusions, since the file labels this item as disclosed.